FDA Panel Backs BPC-157, TB-500 and KPV for the 503A List

On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee voted on seven peptides and recommended six of them for the 503A Bulks List. BPC-157, KPV and TB-500 were all in that six.

If you use one of those three, or you read our coverage of what the committee was set to review going into the meeting, that vote is the headline. It is also smaller than it sounds. Nothing about the legal status of these substances changed on July 24. Here is what the committee actually did, and what would still have to happen before anything is different at the pharmacy counter.

What the committee was voting on

The 503A Bulks List matters because of how the law is written. Under section 503A of the Federal Food, Drug, and Cosmetic Act, FDA describes three routes by which a state-licensed pharmacist may compound with a bulk drug substance: the substance complies with a USP or NF monograph, or it is a component of an FDA-approved drug product when no monograph exists, or it appears on FDA's 503A Bulks List. Peptides like BPC-157 have no monograph and are not components of an approved drug, so the list is the only door available to them, and FDA can only open that door through notice-and-comment rulemaking.

Each substance was nominated and reviewed for a specific use, not for general use. Per FDA's meeting page, the seven and their evaluated uses were:

• BPC-157: ulcerative colitis
• KPV: wound healing and inflammatory conditions
• TB-500: wound healing
• MOTs-c: obesity and osteoporosis
• Emideltide (DSIP): opioid withdrawal, chronic insomnia and narcolepsy
• Semax: cerebral ischemia, migraine and trigeminal neuralgia
• Epitalon: insomnia

That framing is worth registering. A nominated use is the question put to the committee, not a finding that the substance works for it, and in several cases the nominated use is narrower than what these peptides are popularly discussed for.

The tallies

The vote counts come from McDermott Will & Schulte's writeup of the meeting, with the July 23 numbers independently confirmed by Pharmaceutical Executive:

1. 1.BPC-157: 8 in favor, 6 against, 1 abstention. Recommended.
2. 2.KPV: 8 in favor, 6 against, 1 abstention. Recommended.
3. 3.TB-500: 8 in favor, 6 against, 1 abstention. Recommended.
4. 4.MOTs-c: 7 in favor, 5 against, 2 abstentions. Recommended.
5. 5.Semax: 8 in favor, 5 against, 1 abstention. Recommended.
6. 6.Epitalon: 7 in favor, 4 against, 1 abstention. Recommended.
7. 7.Emideltide: 6 in favor, 7 against, 1 abstention. Not recommended.

These were close votes. McDermott also reports something that got less attention than the tallies: in every one of the seven cases, FDA's own scientific reviewers had recommended against inclusion, citing insufficient safety and effectiveness data. The committee voted the other way on six of them.

A recommendation is not an approval

None of these peptides is an FDA-approved drug, and the July votes did not change that. The committee was asked whether a compounding pharmacy should be permitted to work with the raw substance, not whether the substance is safe or effective for anyone.

FDA's own meeting page states the limit plainly: "Advisory committees make non-binding recommendations to the FDA, which generally follows the recommendations but is not legally bound to do so." Writing on July 29, the firm Mintz made the same point about status, noting that an advisory committee vote is not an agency action and that nothing has legally changed yet, because FDA still has to decide whether to accept or reject the recommendations. Pharmaceutical Executive was equally direct: the panel's recommendation is not FDA approval and is not a demonstration of clinical benefit.

What would have to happen next

To actually add these substances to the 503A Bulks List, FDA has to run notice-and-comment rulemaking: publish a proposed rule, take public comment, then issue a final rule.

How long that takes is an estimate, not a schedule. Dustin Robinson of LumaLex Law told Pharmaceutical Executive that the cycle realistically runs eight to twelve months before 503A pharmacies would have unambiguous legal authority to compound these substances. McDermott put a wider band on it, saying a final rule could come in 2027 or stretch into a multi-year process.

In the meantime, FDA's interim enforcement policy still governs. FDA sorts nominated substances into Category 1, where it does not intend to take action against compounders while it finishes evaluating, and Category 2, where it has identified significant safety risks and reserves its enforcement authority. Robinson's framing is useful here: removal from Category 2, a PCAC recommendation, and actual placement on the list through rulemaking are three separate legal events, and it is easy to hear about one and assume the others followed.

Mintz also reports that a second PCAC meeting covering five additional peptides is expected to be scheduled for February 2027.

What this means if you are using or considering one of these

As of August 2026, the regulatory status of BPC-157, KPV and TB-500 is what it was in June. A committee has made a recommendation. FDA has not acted on it.

The honest limits are worth stating together. Six close votes, taken over the objection of FDA's own reviewers, tell you that a panel found the case for permitting compounding good enough. They do not tell you that these peptides work, and the reviewers who looked at the data said there was not enough of it to conclude much about safety or effectiveness. The published timelines are informed guesses from lawyers watching the process, not commitments from the agency. And a rule, if it comes, would cover a specific substance for a specific evaluated use, which may not be the reason you are interested in it.

If you are already taking one of these, the person who prescribed it is the one who can tell you what pathway your prescription actually depends on and what changes, or does not, when a rule lands. That conversation is worth having now rather than after the Federal Register notice appears.